Molecular glues are monovalent small molecules with drug-like properties that alter the protein binding surface of E3 ligase, resulting in novel E3 ligase and target protein interactions. Molecular glues are difficult to design and are often discovered retrospectively. The rational design and discovery of molecular glues require an untargeted approach to understand the protein ternary complexes, target protein degradation, and ubiquitination induced by potential molecular glues. We have leveraged untargeted, high-throughput proteomic approaches to better understand protein-protein interactions and target protein degradation induced by prospective molecular glues. The recent developments in the field of high-throughput proteomics due to the introduction of faster and more sensitive mass spectrometers have brought us closer to the rational design and discovery of molecular glues.
Webinar learning objectives:
Sr Scientist Aman Makaju, Amgen, Discovery Proteomics Group, R&D
Aman Makaju plays a crucial role in supporting Amgen’s Drug Discovery pipeline through the application of mass spectrometry-based proteomics. He is an integral part of a dynamic team that has successfully developed a cutting-edge, high-throughput mass spectrometry-based proteomics platform.